Morgan Stanley has reduced its stake in Stoke Therapeutics, reflecting changes in investment strategies within the pharmaceutical preparations sector.
| Name | Stoke Therapeutics, Inc. |
|---|---|
| CIK | 0001623526 |
| Tickers | STOK |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 471144582 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 781-430-8200 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Morgan Stanley has reduced its stake in Stoke Therapeutics, reflecting changes in investment strategies within the pharmaceutical preparations sector.
FMR LLC has disclosed a 7.5% ownership stake in Stoke Therapeutics, signaling increased investor confidence in the pharmaceutical sector.
Stoke Therapeutics has filed a Form 144, indicating a proposed sale of securities, potentially affecting stakeholders and the pharmaceutical industry.
636 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-128366 | 005-91051 | 261561462 | 34 | 15908 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902219-26-000384 | 005-91051 | 261557887 | 34 | 17322 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001493215-26-000208 | 005-91051 | 261555756 | 34 | 11163 | |||
| 2026-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000895421-26-000321 | 005-91051 | 261553412 | 34 | 12323 | |||
| 2026-11-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002860 | 005-91051 | 261526343 | 34 | 11675 | |||
| 2026-11-04 | 4 | xslF345X06/form4-11042026_041102.xml | 0001780088-26-000025 | 7308 | ||||||
| 2026-11-03 | 10-Q | 10-Q | 0001193125-26-445326 | 001-38938 | 261517331 | 34 | 10217005 | 1 | 1 | |
| 2026-10-29 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-437775 | 001-38938 | 261501677 | 34 | 556142 | 1 | 1 |
| 2026-10-21 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-010349 | 001-38938 | 261476202 | 33 | 14072 | |||
| 2026-10-02 | 4 | xslF345X06/form4-10022026_091025.xml | 0001966716-26-000014 | 4978 | ||||||
| 2026-10-02 | 4 | xslF345X06/form4-10022026_091051.xml | 0001780088-26-000023 | 5514 | ||||||
| 2026-10-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-010004 | 001-38938 | 261436803 | 33 | 5488 | |||
| 2026-09-30 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-002685 | 005-91051 | 261428499 | 34 | 38314 | |||
| 2026-09-25 | 4 | xslF345X06/form4-09252026_080935.xml | 0001685994-26-000009 | 5732 | ||||||
| 2026-09-25 | 3 | xslF345X06/form3-09252026_080902.xml | 0001685994-26-000007 | 10461 | ||||||
| 2026-09-25 | 8-K | 8-K | 5.02 | 0001193125-26-402820 | 001-38938 | 261410391 | 34 | 137396 | 1 | 1 |
| 2026-09-03 | 4 | xslF345X06/form4-09032026_080910.xml | 0001780088-26-000021 | 7309 | ||||||
| 2026-08-18 | 4 | xslF345X06/form4-08192026_120845.xml | 0001780088-26-000019 | 11469 | ||||||
| 2026-08-18 | 4 | xslF345X06/form4-08192026_120851.xml | 0001522780-26-000007 | 11467 | ||||||
| 2026-08-18 | 4 | xslF345X06/form4-08192026_120818.xml | 0001966716-26-000012 | 11466 | ||||||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902664-26-003525 | 005-91051 | 261282701 | 34 | 10672 | |||
| 2026-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000947263-26-000071 | 005-91051 | 261267557 | 34 | 11053 | |||
| 2026-08-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002141 | 005-91051 | 261247250 | 34 | 11668 | |||
| 2026-08-05 | 4 | xslF345X06/form4-08052026_080835.xml | 0001780088-26-000017 | 7309 | ||||||
| 2026-08-03 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-330804 | 001-38938 | 261234288 | 34 | 174714 | 1 | 1 |
| 2026-08-03 | 424B5 | 424B5 | 0001193125-26-330792 | 333-294402 | 261234263 | 33 | 719614 | 1 | 1 | |
| 2026-08-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007565 | 001-38938 | 261233871 | 33 | 6785 | |||
| 2026-08-03 | S-8 | S-8 | 0001193125-26-330706 | 333-297931 | 261233700 | 33 | 411964 | 1 | 1 | |
| 2026-08-03 | 10-Q | 10-Q | 0001193125-26-330557 | 001-38938 | 261232888 | 34 | 9339867 | 1 | 1 | |
| 2026-08-03 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-330537 | 001-38938 | 261232796 | 34 | 543339 | 1 | 1 |
| 2026-07-17 | 4 | xslF345X06/form4-07172026_080716.xml | 0001404955-26-000006 | 40541 | ||||||
| 2026-07-17 | 4 | xslF345X06/form4-07172026_080754.xml | 0001858760-26-000008 | 5693 | ||||||
| 2026-07-17 | 3 | xslF345X06/form3-07172026_080707.xml | 0001858760-26-000007 | 10244 | ||||||
| 2026-07-06 | 4 | xslF345X06/form4-07062026_080747.xml | 0001780088-26-000015 | 7308 | ||||||
| 2026-07-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006742 | 001-38938 | 261146108 | 33 | 6202 | |||
| 2026-06-30 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-289409 | 001-38938 | 261138055 | 34 | 166728 | 1 | 1 |
| 2026-06-18 | 4 | xslF345X06/form4-06182026_080652.xml | 0001966716-26-000010 | 4979 | ||||||
| 2026-06-16 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006194 | 001-38938 | 261095110 | 33 | 7564 | |||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080612.xml | 0001586226-26-000004 | 5693 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080637.xml | 0001557928-26-000002 | 5676 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080631.xml | 0001181556-26-000007 | 5746 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080620.xml | 0001780081-26-000006 | 5692 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080652.xml | 0001522780-26-000004 | 5695 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080609.xml | 0001404955-26-000002 | 5670 | ||||||
| 2026-06-05 | 4 | xslF345X06/form4-06052026_080621.xml | 0001640069-26-000002 | 5695 | ||||||
| 2026-06-04 | 8-K | 8-K | 5.07 | 0001193125-26-257394 | 001-38938 | 261064979 | 34 | 141184 | 1 | 1 |
| 2026-06-03 | 4 | xslF345X06/form4-06032026_090641.xml | 0001780088-26-000013 | 4981 | ||||||
| 2026-05-18 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902664-26-002559 | 005-91051 | 26995686 | 34 | 11127 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902664-26-002530 | 005-91051 | 26988434 | 34 | 10698 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-062573 | 005-91051 | 26987808 | 34 | 12283 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000947263-26-000048 | 005-91051 | 26985428 | 34 | 10903 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001493215-26-000118 | 005-91051 | 26982595 | 34 | 11160 | |||
| 2026-05-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902219-26-000132 | 005-91051 | 26982174 | 34 | 17180 | |||
| 2026-05-07 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-212020 | 001-38938 | 26953741 | 34 | 456195 | 1 | 1 |
| 2026-05-07 | 10-Q | 10-Q | 0001193125-26-211874 | 001-38938 | 26953153 | 34 | 10379645 | 1 | 1 | |
| 2026-05-05 | 4 | xslF345X06/form4-05052026_080522.xml | 0001780088-26-000011 | 4980 | ||||||
| 2026-05-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003920 | 001-38938 | 26933412 | 33 | 7577 | |||
| 2026-04-22 | ARS | ARS | 0001193125-26-170416 | 001-38938 | 26883913 | 34 | 1113972 | |||
| 2026-04-22 | DEFA14A | DEFA14A | 0001193125-26-170393 | 001-38938 | 26883843 | 34 | 696849 | |||
| 2026-04-22 | DEF 14A | DEF 14A | 0001193125-26-170362 | 001-38938 | 26883755 | 34 | 4623575 | 1 | 1 | |
| 2026-04-07 | 4 | xslF345X06/form4-04072026_110410.xml | 0001849236-26-000004 | 5708 | ||||||
| 2026-04-07 | 3 | xslF345X06/form3-04072026_110409.xml | 0001849236-26-000002 | 10245 | ||||||
| 2026-04-07 | 8-K | 8-K | 5.02,7.01,9.01 | 0001193125-26-145524 | 001-38938 | 26844744 | 34 | 160861 | 1 | 1 |
| 2026-04-03 | 4 | xslF345X06/form4-04032026_080432.xml | 0001780088-26-000009 | 4980 | ||||||
| 2026-04-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003143 | 001-38938 | 26828913 | 33 | 6873 | |||
| 2026-03-27 | 8-K | 8-K | 4.01,9.01 | 0001193125-26-129168 | 001-38938 | 26807869 | 34 | 141474 | 1 | 1 |
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-002350 | 005-91051 | 26804605 | 34 | 7172 | |||
| 2026-03-24 | 4 | xslF345X06/form4-03242026_080316.xml | 0001966716-26-000008 | 7307 | ||||||
| 2026-03-20 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002862 | 001-38938 | 26778687 | 33 | 6171 | |||
| 2026-03-19 | 4 | xslF345X06/form4-03192026_100350.xml | 0001780088-26-000006 | 17751 | ||||||
| 2026-03-19 | 4 | xslF345X06/form4-03192026_100335.xml | 0001774690-26-000006 | 12340 | ||||||
| 2026-03-19 | 4 | xslF345X06/form4-03192026_090337.xml | 0001762572-26-000006 | 12328 | ||||||
| 2026-03-19 | 4 | xslF345X06/form4-03192026_090304.xml | 0001966716-26-000006 | 12330 | ||||||
| 2026-03-19 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002826 | 001-38938 | 26774495 | 33 | 5379 | |||
| 2026-03-18 | S-3ASR | S-3ASR | 0001193125-26-113933 | 333-294402 | 26768930 | 33 | 1128525 | 1 | 1 | |
| 2026-03-17 | 4 | xslF345X05/form4-03172026_090347.xml | 0001762572-26-000004 | 7436 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_090359.xml | 0001774690-26-000004 | 7176 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_090316.xml | 0001780088-26-000004 | 14775 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_090329.xml | 0001522780-26-000002 | 10964 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_090341.xml | 0001966716-26-000004 | 15038 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_090352.xml | 0001181556-26-000005 | 5645 | ||||||
| 2026-03-16 | S-8 | S-8 | 0001193125-26-108667 | 333-294359 | 26758067 | 33 | 203228 | 1 | 1 | |
| 2026-03-16 | 10-K | 10-K | 0001193125-26-108362 | 001-38938 | 26756875 | 34 | 15736619 | 1 | 1 | |
| 2026-03-13 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002580 | 001-38938 | 26752737 | 33 | 4854 | |||
| 2026-03-12 | 4 | xslF345X05/form4-03122026_080323.xml | 0001586226-26-000002 | 9117 | ||||||
| 2026-03-12 | 4 | xslF345X05/form4-03122026_080302.xml | 0001780081-26-000004 | 5390 | ||||||
| 2026-03-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002448 | 001-38938 | 26739940 | 33 | 5640 | |||
| 2026-03-04 | 4 | xslF345X05/form4-03042026_090337.xml | 0001780081-26-000002 | 5389 | ||||||
| 2026-03-03 | 8-K | 8-K | 5.02 | 0001193125-26-088205 | 001-38938 | 26714179 | 34 | 133264 | 1 | 1 |
| 2026-03-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002030 | 001-38938 | 26708526 | 33 | 4798 | |||
| 2026-02-19 | 4 | xslF345X05/form4-02192026_090252.xml | 0001780088-26-000002 | 8096 | ||||||
| 2026-02-19 | 4 | xslF345X05/form4-02192026_090250.xml | 0001197032-26-000002 | 8106 | ||||||
| 2026-02-19 | 4 | xslF345X05/form4-02192026_090230.xml | 0001774690-26-000002 | 8107 | ||||||
| 2026-02-19 | 4 | xslF345X05/form4-02192026_090202.xml | 0001762572-26-000002 | 8095 | ||||||
| 2026-02-19 | 4 | xslF345X05/form4-02192026_090202.xml | 0001966716-26-000002 | 8096 | ||||||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-016426 | 005-91051 | 26641394 | 34 | 15062 | |||
| 2026-02-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-26-000519 | 005-91051 | 26602043 | 34 | 11585 | |||
| 2026-01-26 | 8-K | 8-K | 1.01,2.03 | 0001193125-26-022569 | 001-38938 | 26560573 | 34 | 134909 | 1 | 1 |
| 2026-01-12 | 8-K | 8-K | 2.02,7.01,8.01,9.01 | 0001193125-26-009781 | 001-38938 | 26524681 | 34 | 177002 | 1 | 1 |
| 2026-01-05 | 4 | xslF345X05/form4-01052026_090116.xml | 0001181556-26-000003 | 7951 | ||||||
| 2025-12-10 | 4 | xslF345X05/form4-12102025_091230.xml | 0001966716-25-000009 | 7172 | ||||||
| 2025-12-10 | 4 | xslF345X05/form4-12102025_091241.xml | 0001522780-25-000010 | 8934 | ||||||
| 2025-12-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009955 | 001-38938 | 251556611 | 33 | 9643 | |||
| 2025-12-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009951 | 001-38938 | 251556589 | 33 | 8948 | |||
| 2025-12-05 | 4 | xslF345X05/form4-12062025_011222.xml | 0001780088-25-000006 | 14660 | ||||||
| 2025-12-05 | 4 | xslF345X05/form4-12062025_011216.xml | 0001522780-25-000009 | 16648 | ||||||
| 2025-12-05 | 4 | xslF345X05/form4-12062025_011219.xml | 0001966716-25-000008 | 16650 | ||||||
| 2025-12-05 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009875 | 001-38938 | 251553502 | 33 | 7574 | |||
| 2025-12-05 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009869 | 001-38938 | 251553366 | 33 | 6874 | |||
| 2025-12-05 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009868 | 001-38938 | 251553362 | 33 | 7559 | |||
| 2025-12-05 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-308781 | 001-38938 | 251551357 | 34 | 205548 | 1 | 1 |
| 2025-12-03 | 4 | xslF345X05/form4-12042025_011237.xml | 0001780088-25-000005 | 14700 | ||||||
| 2025-12-03 | 4 | xslF345X05/form4-12042025_011205.xml | 0001522780-25-000008 | 14688 | ||||||
| 2025-12-03 | 4 | xslF345X05/form4-12042025_011223.xml | 0001966716-25-000006 | 14716 | ||||||
| 2025-11-26 | 4 | xslF345X05/form4-11262025_091144.xml | 0001780081-25-000006 | 5391 | ||||||
| 2025-11-24 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009261 | 001-38938 | 251513372 | 33 | 5504 | |||
| 2025-11-18 | 4 | xslF345X05/form4-11182025_091122.xml | 0001780081-25-000004 | 7174 | ||||||
| 2025-11-14 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008873 | 001-38938 | 251486988 | 33 | 4797 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001771015-25-000011 | 005-91051 | 251482935 | 34 | 6969 | |||
| 2025-11-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000947263-25-000009 | 005-91051 | 251482900 | 34 | 7167 | |||
| 2025-11-05 | 4 | xslF345X05/form4-11052025_091154.xml | 0001780088-25-000004 | 10458 | ||||||
| 2025-11-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-002853 | 005-91051 | 251452824 | 34 | 11590 | |||
| 2025-11-04 | 10-Q | 10-Q | 0001193125-25-264720 | 001-38938 | 251449292 | 34 | 9531865 | 1 | 1 | |
| 2025-11-04 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-264644 | 001-38938 | 251448919 | 34 | 482431 | 1 | 1 |
| 2025-11-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008382 | 001-38938 | 251444434 | 33 | 6877 | |||
| 2025-10-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-25-002708 | 005-91051 | 251401890 | 34 | 10974 | |||
| 2025-10-14 | 4 | xslF345X05/form4-10142025_081006.xml | 0001197032-25-000004 | 8115 | ||||||
| 2025-10-10 | 4 | xslF345X05/form4-10102025_081021.xml | 0001522780-25-000007 | 8826 | ||||||
| 2025-10-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007849 | 001-38938 | 251382548 | 33 | 8305 | |||
| 2025-10-07 | 4 | xslF345X05/form4-10072025_081055.xml | 0001522780-25-000004 | 5362 | ||||||
| 2025-10-07 | 4 | xslF345X05/form4-10072025_081001.xml | 0001966716-25-000004 | 9319 | ||||||
| 2025-10-06 | 8-K | 8-K | 5.02,9.01 | 0001193125-25-230925 | 001-38938 | 251375616 | 34 | 260094 | 1 | 1 |
| 2025-10-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007743 | 001-38938 | 251374484 | 33 | 7598 | |||
| 2025-10-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007742 | 001-38938 | 251374402 | 33 | 8535 | |||
| 2025-10-03 | 4 | xslF345X05/form4-10032025_081034.xml | 0001780088-25-000003 | 5400 | ||||||
| 2025-10-01 | 4 | xslF345X05/form4-10012025_081019.xml | 0001181556-25-000006 | 7955 | ||||||
| 2025-09-18 | 8-K/A | 8-K/A | 5.07 | 0001193125-25-207401 | 001-38938 | 251323516 | 34 | 140456 | 1 | 1 |
| 2025-09-05 | 4 | xslF345X05/form4-09052025_080918.xml | 0001415889-25-023792 | 8987 | ||||||
| 2025-09-03 | 4 | xslF345X05/form4-09032025_090900.xml | 0001415889-25-023591 | 5400 | ||||||
| 2025-09-03 | 4 | xslF345X05/form4-09032025_090950.xml | 0001415889-25-023590 | 8657 | ||||||
| 2025-09-03 | 4 | xslF345X05/form4-09032025_090917.xml | 0001415889-25-023589 | 16101 | ||||||
| 2025-09-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006649 | 001-38938 | 251286111 | 33 | 8909 | |||
| 2025-08-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006558 | 001-38938 | 251281129 | 33 | 6811 | |||
| 2025-08-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006555 | 001-38938 | 251281115 | 33 | 7013 | |||
| 2025-08-26 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001123292-25-000387 | 005-91051 | 251258919 | 34 | 34004 | |||
| 2025-08-20 | 4 | xslF345X05/form4-08202025_080828.xml | 0001415889-25-022442 | 5142 | ||||||
| 2025-08-20 | 4 | xslF345X05/form4-08202025_080810.xml | 0001415889-25-022441 | 5103 | ||||||
| 2025-08-20 | 4 | xslF345X05/form4-08202025_080802.xml | 0001415889-25-022440 | 5142 | ||||||
| 2025-08-18 | 4 | xslF345X05/form4-08192025_120854.xml | 0001415889-25-022227 | 9494 | ||||||
| 2025-08-18 | 4 | xslF345X05/form4-08192025_120830.xml | 0001415889-25-022226 | 9490 | ||||||
| 2025-08-18 | 4 | xslF345X05/form4-08192025_120819.xml | 0001415889-25-022225 | 9454 | ||||||
| 2025-08-15 | 4 | xslF345X05/form4-08152025_080840.xml | 0001415889-25-022074 | 5112 | ||||||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-078641 | 005-91051 | 251219546 | 34 | 13048 | |||
| 2025-08-13 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-005776 | 001-38938 | 251212125 | 33 | 5385 | |||
| 2025-08-12 | 10-Q | 10-Q | 0000950170-25-107332 | 001-38938 | 251206912 | 34 | 9486066 | 1 | 1 | |
| 2025-08-12 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-25-107275 | 001-38938 | 251206495 | 34 | 17924529 | 1 | 1 |
| 2025-08-11 | 8-K | 8-K | 7.01,9.01 | 0001193125-25-177433 | 001-38938 | 251200085 | 34 | 174734 | 1 | 1 |
| 2025-08-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-002118 | 005-91051 | 251188478 | 34 | 11178 | |||
| 2025-08-05 | 4 | xslF345X05/form4-08052025_080805.xml | 0001415889-25-021024 | 5400 | ||||||
| 2025-07-29 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001085146-25-004276 | 005-91051 | 251162916 | 34 | 6629 | |||
| 2025-07-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-002218 | 005-91051 | 251125556 | 34 | 10864 | |||
| 2025-07-11 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-002242 | 333-288583 | 251120049 | 33 | 1811 | ||
| 2025-07-10 | 8-K | 8-K | 7.01,9.01 | 0001193125-25-157364 | 001-38938 | 251114804 | 34 | 171727 | 1 | 1 |
| 2025-07-09 | CORRESP | filename1.htm | 0001193125-25-157116 | 9790 | ||||||
| 2025-07-09 | S-8 | S-8 | 0001193125-25-157079 | 333-288584 | 251113636 | 33 | 292109 | |||
| 2025-07-09 | S-3 | S-3 | 0001193125-25-157072 | 333-288583 | 251113602 | 33 | 948388 | |||
| 2025-07-02 | 4 | xslF345X05/form4-07022025_080730.xml | 0001415889-25-019004 | 5400 | ||||||
| 2025-07-02 | 4 | xslF345X05/form4-07022025_080722.xml | 0001415889-25-019002 | 7917 | ||||||
| 2025-07-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004760 | 001-38938 | 251096762 | 33 | 7592 | |||
| 2025-06-30 | UPLOAD | filename1.pdf | 0000000000-25-006891 | 377-08144 | 40335 | |||||
| 2025-06-26 | DRSLTR | filename1.htm | 0000950123-25-006123 | 9986 | ||||||
| 2025-06-26 | DRS | filename1.htm | 0000950123-25-006122 | 377-08144 | 251080860 | 33 | 879181 | |||
| 2025-06-23 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001123292-25-000298 | 005-91051 | 251065471 | 34 | 37250 | |||
| 2025-06-23 | 3 | xslF345X02/form3-06232025_080607.xml | 0001415889-25-017957 | 17805 | ||||||
| 2025-06-06 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001123292-25-000272 | 005-91051 | 251031039 | 34 | 35193 | |||
| 2025-06-06 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-011153 | 10829 | ||||||
| 2025-06-06 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-001629 | 005-91051 | 251029169 | 34 | 11422 | |||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120602.xml | 0001415889-25-015702 | 5558 | ||||||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120645.xml | 0001415889-25-015701 | 5571 | ||||||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120640.xml | 0001415889-25-015700 | 5571 | ||||||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120617.xml | 0001415889-25-015699 | 5555 | ||||||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120602.xml | 0001415889-25-015698 | 5533 | ||||||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120657.xml | 0001415889-25-015695 | 5568 | ||||||
| 2025-06-04 | 4 | xslF345X05/form4-06052025_120640.xml | 0001415889-25-015693 | 6909 | ||||||
| 2025-06-04 | 8-K | 8-K | 5.07 | 0001193125-25-134882 | 001-38938 | 251023111 | 34 | 146762 | 1 | 1 |
| 2025-06-04 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-134447 | 001-38938 | 251021874 | 34 | 12164731 | 1 | 1 |
| 2025-05-13 | 10-Q | 10-Q | 0000950170-25-070296 | 001-38938 | 25939964 | 34 | 9145419 | 1 | 1 | |
| 2025-05-13 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-069783 | 001-38938 | 25937094 | 34 | 401520 | 1 | 1 |
| 2025-05-05 | 4 | xslF345X05/form4-05052025_080547.xml | 0001415889-25-011940 | 6909 | ||||||
| 2025-05-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-002674 | 001-38938 | 25903960 | 33 | 6169 | |||
| 2025-04-22 | ARS | ARS | 0001193125-25-089195 | 001-38938 | 25857803 | 34 | 1158562 | |||
| 2025-04-22 | DEFA14A | DEFA14A | 0001193125-25-089192 | 001-38938 | 25857741 | 34 | 1038481 | |||
| 2025-04-22 | DEF 14A | DEF 14A | 0001193125-25-089188 | 001-38938 | 25857714 | 34 | 2920154 | 1 | 1 | |
| 2025-04-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001576419-25-000003 | 005-91051 | 25843866 | 34 | 11181 | |||
| 2025-04-15 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-000328 | 005-91051 | 25840329 | 34 | 10715 | |||
| 2025-04-02 | 4 | xslF345X05/form4-04022025_080412.xml | 0001415889-25-009616 | 7916 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100340.xml | 0001415889-25-008715 | 5524 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100333.xml | 0001415889-25-008714 | 5539 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100358.xml | 0001415889-25-008713 | 8082 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100309.xml | 0001415889-25-008712 | 5721 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100313.xml | 0001415889-25-008711 | 12070 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100314.xml | 0001415889-25-008710 | 12102 | ||||||
| 2025-03-20 | 4 | xslF345X05/form4-03202025_100334.xml | 0001415889-25-008709 | 12102 | ||||||
| 2025-03-18 | S-8 | S-8 | 0001193125-25-056719 | 333-285890 | 25749216 | 33 | 81820 | |||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_080351.xml | 0001415889-25-008367 | 11240 | ||||||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_080350.xml | 0001415889-25-008359 | 10976 | ||||||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_080305.xml | 0001415889-25-008355 | 10939 | ||||||
| 2025-03-18 | 10-K | 10-K | 0000950170-25-041170 | 001-38938 | 25748244 | 34 | 15961432 | 1 | 1 | |
| 2025-03-18 | 8-K | 8-K | 2.02,5.02,7.01,9.01 | 0000950170-25-040758 | 001-38938 | 25746477 | 34 | 476699 | 1 | 1 |
| 2025-02-18 | 8-K | 8-K | 1.01,7.01,8.01,9.01 | 0001193125-25-028650 | 001-38938 | 25635519 | 34 | 197200 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000950170-25-020494 | 005-91051 | 25623687 | 34 | 10926 | |||
| 2025-02-03 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000895421-25-000200 | 005-91051 | 25583091 | 34 | 12017 | |||
| 2025-01-07 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-002550 | 001-38938 | 25513461 | 34 | 4183729 | 1 | 1 |
| 2025-01-02 | 4 | xslF345X05/form4-01022025_090156.xml | 0001415889-25-000084 | 6835 | ||||||
| 2024-12-27 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001123292-24-000417 | 005-91051 | 241586405 | 34 | 22539 | |||
| 2024-12-27 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-021228 | 10785 | ||||||
| 2024-12-23 | 144 | xsl144X01/primary_doc.xml | 0001968582-24-001221 | 001-38938 | 241575188 | 33 | 4635 | |||
| 2024-12-11 | 4 | xslF345X05/form4-12112024_091233.xml | 0001415889-24-028930 | 5435 | ||||||
| 2024-12-11 | 4 | xslF345X05/form4-12112024_091251.xml | 0001415889-24-028929 | 7377 | ||||||
| 2024-12-11 | 4 | xslF345X05/form4-12112024_091247.xml | 0001415889-24-028928 | 5110 | ||||||
| 2024-12-10 | 4 | xslF345X05/form4-12112024_121235.xml | 0001415889-24-028892 | 5429 | ||||||
| 2024-12-10 | 4 | xslF345X05/form4-12112024_121243.xml | 0001415889-24-028891 | 5428 | ||||||
| 2024-12-10 | 4 | xslF345X05/form4-12112024_121241.xml | 0001415889-24-028890 | 5389 | ||||||
| 2024-12-10 | 4/A | xslF345X05/form4a-12102024_111228.xml | 0001415889-24-028889 | 9797 | ||||||
| 2024-12-09 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-009594 | 001-38938 | 241535698 | 33 | 4809 | |||
| 2024-12-06 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-24-272559 | 001-38938 | 241533232 | 34 | 284489 | 1 | 1 |
| 2024-12-05 | 4 | xslF345X05/form4-12052024_091203.xml | 0001415889-24-028398 | 9499 | ||||||
| 2024-12-05 | 4 | xslF345X05/form4-12052024_091208.xml | 0001415889-24-028397 | 9464 | ||||||
| 2024-12-05 | 4 | xslF345X05/form4-12052024_091200.xml | 0001415889-24-028396 | 9503 | ||||||
| 2024-12-03 | 4 | xslF345X05/form4-12032024_091216.xml | 0001415889-24-028071 | 7408 | ||||||
| 2024-12-03 | 4 | xslF345X05/form4-12032024_091257.xml | 0001415889-24-028070 | 7100 | ||||||
| 2024-12-03 | 4 | xslF345X05/form4-12032024_091239.xml | 0001415889-24-028069 | 13200 | ||||||
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001104659-24-119434 | 005-91051 | 241465544 | 34 | 86678 | |||
| 2024-11-14 | SC 13G | SC 13G | 0001104659-24-118991 | 005-91051 | 241462886 | 34 | 94392 | |||
| 2024-11-14 | SC 13G/A | STOKE THERAPEUTICS, INC. | 0000902664-24-006512 | 005-91051 | 241457553 | 34 | 66604 | |||
| 2024-11-12 | SC 13G/A | UnitedStates_13G__StokeThera.txt | 0000932471-24-001280 | 005-91051 | 241450295 | 34 | 6603 | |||
| 2024-11-05 | 4 | xslF345X05/form4-11052024_091125.xml | 0001415889-24-026135 | 9276 | ||||||
| 2024-11-05 | 10-Q | 10-Q | 0000950170-24-121445 | 001-38938 | 241427417 | 34 | 6209106 | 1 | 1 | |
| 2024-11-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-121068 | 001-38938 | 241425594 | 34 | 377982 | 1 | 1 |
| 2024-11-04 | SC 13G/A | UnitedStates_13G__StokeThera.txt | 0000932471-24-000715 | 005-91051 | 241422467 | 34 | 5669 | |||
| 2024-11-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-008040 | 001-38938 | 241419743 | 33 | 6453 | |||
| 2024-10-09 | S-3ASR | S-3ASR | 0001193125-24-235229 | 333-282561 | 241362955 | 33 | 945638 | |||
| 2024-10-02 | 4 | xslF345X05/form4-10022024_081008.xml | 0001415889-24-024378 | 9276 | ||||||
| 2024-09-23 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-016894 | 10784 | ||||||
| 2024-09-23 | SC 13D/A | stoke13d.htm | 0001123292-24-000282 | 005-91051 | 241316485 | 34 | 349104 | |||
| 2024-09-19 | 144 | xsl144X01/primary_doc.xml | 0001968582-24-000850 | 001-38938 | 241311251 | 33 | 4603 | |||
| 2024-09-10 | 8-K | 8-K | 8.01,9.01 | 0001193125-24-216632 | 001-38938 | 241290303 | 34 | 239544 | 1 | 1 |
| 2024-09-05 | 4 | xslF345X05/form4-09052024_080953.xml | 0001415889-24-022900 | 11022 | ||||||
| 2024-08-07 | 10-Q | 10-Q | 0000950170-24-092738 | 001-38938 | 241183564 | 34 | 6257948 | 1 | 1 | |
| 2024-08-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-092268 | 001-38938 | 241181387 | 34 | 375699 | 1 | 1 |
| 2024-08-05 | 4 | xslF345X05/form4-08052024_080835.xml | 0001415889-24-020734 | 9276 | ||||||
| 2024-08-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005746 | 001-38938 | 241167150 | 33 | 6453 | |||
| 2024-07-08 | SC 13G | us86150r1077_070824.txt | 0001086364-24-008222 | 005-91051 | 241105207 | 34 | 13974 | |||
| 2024-07-03 | 4 | xslF345X05/form4-07032024_080758.xml | 0001415889-24-019169 | 7208 | ||||||
| 2024-07-03 | 4 | xslF345X05/form4-07032024_080719.xml | 0001415889-24-019168 | 9276 | ||||||
| 2024-07-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005205 | 001-38938 | 241095528 | 33 | 5517 | |||
| 2024-06-21 | 8-K | 8-K | 5.02 | 0001193125-24-165651 | 001-38938 | 241060181 | 34 | 143919 | 1 | 1 |
| 2024-06-20 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-06-20 16:00:00 | 9999999995-24-001910 | 333-280172 | 241058272 | 33 | 1818 | ||
| 2024-06-17 | CORRESP | filename1.htm | 0001193125-24-162675 | 8452 | ||||||
| 2024-06-17 | UPLOAD | filename1.pdf | 0000000000-24-006938 | 333-280172 | 40297 | |||||
| 2024-06-13 | S-3 | S-3 | 0001193125-24-160696 | 333-280172 | 241041250 | 33 | 245903 | |||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080631.xml | 0001415889-24-016010 | 8047 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080616.xml | 0001415889-24-016008 | 8072 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080653.xml | 0001415889-24-016005 | 8080 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080658.xml | 0001415889-24-015998 | 8080 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080605.xml | 0001415889-24-015995 | 8084 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080638.xml | 0001415889-24-015991 | 12554 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080616.xml | 0001415889-24-015976 | 12591 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080629.xml | 0001415889-24-015974 | 12507 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080629.xml | 0001415889-24-015970 | 12566 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080627.xml | 0001415889-24-015968 | 12522 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080651.xml | 0001415889-24-015965 | 12577 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080608.xml | 0001415889-24-015964 | 12522 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080601.xml | 0001415889-24-015962 | 12510 | ||||||
| 2024-06-06 | 8-K | 8-K | 5.07 | 0001193125-24-156049 | 001-38938 | 241025048 | 34 | 149808 | 1 | 1 |
| 2024-06-05 | 4 | xslF345X05/form4-06052024_080649.xml | 0001415889-24-015559 | 17898 | ||||||
| 2024-05-22 | 4 | xslF345X05/form4-05222024_080503.xml | 0001415889-24-014093 | 16063 | ||||||
| 2024-05-22 | 4 | xslF345X05/form4-05222024_080510.xml | 0001415889-24-014087 | 14428 | ||||||
| 2024-05-22 | 4 | xslF345X05/form4-05222024_080500.xml | 0001415889-24-014082 | 16263 | ||||||
| 2024-05-20 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-003917 | 001-38938 | 24964863 | 33 | 5514 | |||
| 2024-05-20 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-003914 | 001-38938 | 24964826 | 33 | 5516 | |||
| 2024-05-20 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-003913 | 001-38938 | 24964816 | 33 | 6043 | |||
| 2024-05-17 | 4 | xslF345X05/form4-05172024_080515.xml | 0001415889-24-013477 | 5555 | ||||||
| 2024-05-17 | 3 | xslF345X02/form3-05172024_080541.xml | 0001415889-24-013475 | 10445 | ||||||
| 2024-05-06 | 10-Q | 10-Q | 0000950170-24-053535 | 001-38938 | 24917484 | 34 | 5649750 | 1 | 1 | |
| 2024-05-06 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-053195 | 001-38938 | 24915518 | 34 | 342630 | 1 | 1 |
| 2024-05-03 | 4 | xslF345X05/form4-05032024_080531.xml | 0001415889-24-012173 | 9277 | ||||||
| 2024-05-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-003280 | 001-38938 | 24903468 | 33 | 7129 | |||
| 2024-04-29 | 8-K | 8-K | 5.02 | 0001193125-24-122215 | 001-38938 | 24890614 | 34 | 152791 | 1 | 1 |
| 2024-04-23 | ARS | ARS | 0001193125-24-107021 | 001-38938 | 24864925 | 34 | 11772242 | |||
| 2024-04-23 | DEFA14A | DEFA14A | 0001193125-24-106991 | 001-38938 | 24864892 | 34 | 444620 | |||
| 2024-04-23 | DEF 14A | DEF 14A | 0001193125-24-106979 | 001-38938 | 24864857 | 34 | 762440 | |||
| 2024-04-18 | SC 13D/A | stoke13d.htm | 0001123292-24-000113 | 005-91051 | 24854522 | 34 | 177609 | |||
| 2024-04-18 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-008547 | 10781 | ||||||
| 2024-04-17 | 144 | xsl144X01/primary_doc.xml | 0001968582-24-000320 | 001-38938 | 24851280 | 33 | 4616 | |||
| 2024-04-11 | S-8 | S-8 | 0001193125-24-093195 | 333-278619 | 24838548 | 33 | 82703 | |||
| 2024-04-03 | 4 | xslF345X05/form4-04032024_080444.xml | 0001415889-24-009999 | 9270 | ||||||
| 2024-04-03 | 4 | xslF345X05/form4-04032024_080414.xml | 0001415889-24-009993 | 10565 | ||||||
| 2024-04-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-002817 | 001-38938 | 24810054 | 33 | 5983 | |||
| 2024-04-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-002782 | 001-38938 | 24809705 | 33 | 7515 | |||
| 2024-04-01 | 4 | xslF345X05/form4-04012024_080416.xml | 0001415889-24-009532 | 6927 | ||||||
| 2024-03-28 | 8-K | 8-K | 1.01,7.01,9.01 | 0001193125-24-080874 | 001-38938 | 24800474 | 34 | 517613 | 1 | 1 |
| 2024-03-28 | 424B5 | 424B5 | 0001193125-24-080862 | 333-265107 | 24800364 | 33 | 546418 | |||
| 2024-03-28 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-002743 | 001-38938 | 24799778 | 33 | 4805 | |||
| 2024-03-28 | FWP | FWP | 0001193125-24-079032 | 333-265107 | 24792492 | 34 | 61209 | |||
| 2024-03-26 | 424B5 | 424B5 | 0001193125-24-077675 | 333-265107 | 24784321 | 33 | 522708 | |||
| 2024-03-25 | 10-K | 10-K | 0000950170-24-035912 | 001-38938 | 24779274 | 34 | 11767600 | 1 | 1 | |
| 2024-03-25 | 8-K | 8-K | 7.01,9.01 | 0001193125-24-076478 | 001-38938 | 24779273 | 34 | 3220217 | 1 | 1 |
| 2024-03-25 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-035908 | 001-38938 | 24779171 | 34 | 350240 | 1 | 1 |
| 2024-03-19 | 4 | xslF345X05/form4-03202024_120350.xml | 0001415889-24-008690 | 9416 | ||||||
| 2024-03-19 | 4 | xslF345X05/form4-03202024_120307.xml | 0001415889-24-008689 | 9420 | ||||||
| 2024-03-19 | 4 | xslF345X05/form4-03202024_120349.xml | 0001415889-24-008686 | 9684 | ||||||
| 2024-03-19 | 4 | xslF345X05/form4-03202024_120318.xml | 0001415889-24-008683 | 9383 | ||||||
| 2024-03-19 | 4 | xslF345X05/form4-03202024_120354.xml | 0001415889-24-008681 | 9706 | ||||||
| 2024-03-05 | 4 | xslF345X05/form4-03052024_090335.xml | 0001415889-24-006623 | 9271 | ||||||
| 2024-03-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-001653 | 001-38938 | 24710334 | 33 | 6813 | |||
| 2024-02-26 | SC 13G/A | COWEN FINANCIAL PRODUCTS LLC | 0001085146-24-001540 | 005-91051 | 24674657 | 34 | 27364 | |||
| 2024-02-26 | SC 13G | COWEN FINANCIAL PRODUCTS LLC | 0001085146-24-001539 | 005-91051 | 24674651 | 34 | 27302 | |||
| 2024-02-15 | 4 | xslF345X05/form4-02152024_090236.xml | 0001415889-24-003897 | 7040 | ||||||
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001104659-24-023778 | 005-91051 | 24638915 | 34 | 102402 | |||
| 2024-02-14 | SC 13G/A | STOKE THERAPEUTICS, INC. | 0000902664-24-001610 | 005-91051 | 24633033 | 34 | 64836 | |||
| 2024-02-14 | SC 13G/A | STOKE THERAPEUTICS, INC. | 0000902664-24-001571 | 005-91051 | 24632360 | 34 | 64487 | |||
| 2024-02-09 | SC 13G/A | MS AMENDMENT | 0000895421-24-000165 | 005-91051 | 24614170 | 34 | 17612 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001457 | 005-91051 | 24612039 | 34 | 8252 | |||
| 2024-02-05 | 4 | xslF345X05/form4-02052024_090232.xml | 0001415889-24-002531 | 5399 | ||||||
| 2024-02-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-000596 | 001-38938 | 24587660 | 33 | 5518 | |||
| 2024-01-08 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-24-003939 | 001-38938 | 24518440 | 34 | 9100876 | 1 | 1 |
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000801 | 5751 | ||||||
| 2024-01-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-000023 | 001-38938 | 24502866 | 33 | 4809 | |||
| 2023-12-14 | 8-K | 8-K | 1.01,2.03 | 0001193125-23-295456 | 001-38938 | 231487116 | 34 | 145870 | 1 | 1 |
| 2023-12-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-057410 | 13823 | ||||||
| 2023-12-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-057407 | 13828 | ||||||
| 2023-12-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-057403 | 8352 | ||||||
| 2023-12-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-057396 | 8330 | ||||||
| 2023-12-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-057387 | 11120 | ||||||
| 2023-12-05 | SC TO-I/A | SC TO-I/A | 0001193125-23-289154 | 005-91051 | 231466642 | 34 | 19042 | |||
| 2023-12-01 | 8-K | 8-K | 7.01,9.01 | 0001193125-23-286862 | 001-38938 | 231457707 | 34 | 196901 | 1 | 1 |
| 2023-11-17 | SC TO-I/A | SC TO-I/A | 0001193125-23-279830 | 005-91051 | 231419382 | 34 | 98796 | |||
| 2023-11-17 | CORRESP | filename1.htm | 0001193125-23-279827 | 40169 | ||||||
| 2023-11-16 | UPLOAD | filename1.pdf | 0000000000-23-012558 | 56292 | ||||||
| 2023-11-09 | SC TO-I/A | SC TO-I/A | 0001193125-23-274539 | 005-91051 | 231393011 | 34 | 34117 | |||
| 2023-11-07 | 10-Q | 10-Q | 0000950170-23-060224 | 001-38938 | 231383638 | 34 | 7134921 | 1 | 1 | |
| 2023-11-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-059756 | 001-38938 | 231381513 | 34 | 468244 | 1 | 1 |
| 2023-11-06 | SC 13G | STOKE THERAPEUTICS, INC. | 0000902664-23-005344 | 005-91051 | 231380585 | 34 | 67250 | |||
| 2023-11-02 | SC TO-I | SC TO-I | 0001193125-23-268930 | 005-91051 | 231370314 | 34 | 18395369 | |||
| 2023-10-26 | 8-K | 8-K | 5.07 | 0001193125-23-264160 | 001-38938 | 231350885 | 34 | 145969 | 1 | 1 |
| 2023-09-28 | DEF 14A | DEF 14A | 0001193125-23-245609 | 001-38938 | 231289508 | 34 | 580710 | |||
| 2023-09-20 | 4 | FORM 4 SUBMISSION | 0001209191-23-050170 | 5488 | ||||||
| 2023-09-20 | 3 | FORM 3 SUBMISSION | 0001209191-23-050166 | 5922 | ||||||
| 2023-09-20 | 8-K | 8-K | 5.02,9.01 | 0001193125-23-238627 | 001-38938 | 231266885 | 34 | 161344 | 1 | 1 |
| 2023-09-18 | PRE 14A | PRE 14A | 0001193125-23-236901 | 001-38938 | 231261229 | 34 | 580013 | |||
| 2023-09-08 | 4 | FORM 4 SUBMISSION | 0001209191-23-048770 | 7076 | ||||||
| 2023-08-07 | 10-Q | 10-Q | 0000950170-23-039050 | 001-38938 | 231147626 | 34 | 7981989 | 1 | 1 | |
| 2023-08-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-038733 | 001-38938 | 231145561 | 34 | 540274 | 1 | 1 |
| 2023-07-25 | 8-K | 8-K | 7.01,9.01 | 0001193125-23-192735 | 001-38938 | 231106439 | 34 | 4170669 | 1 | 1 |
| 2023-07-06 | 4 | FORM 4 SUBMISSION | 0001209191-23-041616 | 5376 | ||||||
| 2023-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-23-039428 | 5386 | ||||||
| 2023-06-21 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-001827 | 001-38938 | 231030091 | 33 | 4730 | |||
| 2023-06-20 | 8-K | 8-K | 5.07 | 0001193125-23-170114 | 001-38938 | 231024971 | 34 | 155897 | 1 | 1 |
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037539 | 5452 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037537 | 5454 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037535 | 5467 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037533 | 5467 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037532 | 5451 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037530 | 5429 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037529 | 5464 | ||||||
| 2023-06-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-034648 | 5375 | ||||||
| 2023-05-24 | DEFA14A | DEFA14A | 0001193125-23-153061 | 001-38938 | 23955100 | 34 | 15987 | |||
| 2023-05-08 | 4 | FORM 4 SUBMISSION | 0001209191-23-028111 | 4838 | ||||||
| 2023-05-04 | 10-Q | 10-Q | 0000950170-23-017839 | 001-38938 | 23888659 | 34 | 7661395 | 1 | 1 | |
| 2023-05-04 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-017454 | 001-38938 | 23886396 | 34 | 469865 | 1 | 1 |
| 2023-05-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-027190 | 9570 | ||||||
| 2023-05-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-000361 | 001-38938 | 23884876 | 33 | 6854 | |||
| 2023-04-27 | ARS | ARS | 0001193125-23-122150 | 001-38938 | 23856922 | 34 | 8652665 | |||
| 2023-04-27 | DEFA14A | DEFA14A | 0001193125-23-122102 | 001-38938 | 23856737 | 34 | 792068 | |||
| 2023-04-27 | DEF 14A | DEF 14A | 0001193125-23-122085 | 001-38938 | 23856621 | 34 | 801836 | |||
| 2023-04-17 | PRE 14A | PRE 14A | 0001193125-23-103615 | 001-38938 | 23823938 | 34 | 802045 | |||
| 2023-04-13 | S-8 | S-8 | 0001193125-23-100506 | 333-271237 | 23818360 | 33 | 343279 | |||
| 2023-03-22 | S-8 | S-8 | 0001193125-23-076715 | 333-270744 | 23753190 | 33 | 77492 | |||
| 2023-03-17 | 4 | FORM 4 SUBMISSION | 0001209191-23-019676 | 8087 | ||||||
| 2023-03-17 | 4 | FORM 4 SUBMISSION | 0001209191-23-019669 | 8064 | ||||||
| 2023-03-17 | 4 | FORM 4 SUBMISSION | 0001209191-23-019662 | 8070 | ||||||
| 2023-03-17 | 4 | FORM 4 SUBMISSION | 0001209191-23-019656 | 8061 | ||||||
| 2023-03-17 | 4 | FORM 4 SUBMISSION | 0001209191-23-019653 | 8037 | ||||||
| 2023-03-17 | 3 | FORM 3 SUBMISSION | 0001209191-23-019564 | 10461 | ||||||
| 2023-03-15 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-23-070652 | 001-38938 | 23733257 | 34 | 175618 | 1 | 1 |
| 2023-03-06 | 10-K | 10-K | 0001564590-23-003175 | 001-38938 | 23708934 | 34 | 13196790 | 1 | 1 | |
| 2023-03-06 | 8-K | 8-K | 2.02,9.01 | 0001564590-23-003162 | 001-38938 | 23707531 | 34 | 507954 | 1 | 1 |
| 2023-02-14 | SC 13G/A | STOKE THERAPEUTICS, INC. | 0000902664-23-001724 | 005-91051 | 23623858 | 34 | 65182 | |||
| 2023-02-10 | SC 13G | MS INITIAL | 0000895421-23-000192 | 005-91051 | 23609631 | 34 | 17508 | |||
| 2023-02-09 | SC 13G/A | filing.txt | 0000315066-23-002041 | 005-91051 | 23605025 | 34 | 8040 | |||
| 2023-02-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-017029 | 005-91051 | 23604298 | 34 | 13018 | |||
| 2023-02-07 | 4 | FORM 4 SUBMISSION | 0001209191-23-007597 | 7420 | ||||||
| 2023-02-03 | SC 13G/A | SC 13G/A | 0001104659-23-010642 | 005-91051 | 23587314 | 34 | 90476 | |||
| 2023-02-03 | 8-K | 8-K | 5.03,9.01 | 0001193125-23-024123 | 001-38938 | 23585781 | 34 | 372571 | 1 | 1 |
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006397 | 8446 | ||||||
| 2023-01-25 | SC 13G/A | COWEN FINANCIAL PRODUCTS LLC | 0001085146-23-000369 | 005-91051 | 23552428 | 34 | 27272 | |||
| 2023-01-09 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-23-004192 | 001-38938 | 23516704 | 34 | 8879696 | 1 | 1 |
| 2022-12-09 | 4 | FORM 4 SUBMISSION | 0001209191-22-060548 | 5494 | ||||||
| 2022-12-09 | 4 | FORM 4 SUBMISSION | 0001209191-22-060547 | 5499 |
One latest value per concept from companyfacts (204 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 65.41M | 2026-10-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 592.00M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 9.56M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001193125-26-170362 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 2.05M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001193125-26-170362 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 343.88 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-22 | 0001193125-26-170362 | ||
| ffd | NetFeeAmt | NetFeeAmt | USD | 8,063 | 2026-07-31 | S-8 | 2026-08-03 | 0001193125-26-330706 | |||
| ffd | NrrtvMaxAggtOfferingPric | NrrtvMaxAggtOfferingPric | USD | 200.00M | 2026-07-31 | 424B5 | 2026-08-03 | 0001193125-26-330792 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 8,063 | 2026-07-31 | S-8 | 2026-08-03 | 0001193125-26-330706 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 58.38M | 2026-07-31 | S-8 | 2026-08-03 | 0001193125-26-330706 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-07-31 | S-8 | 2026-08-03 | 0001193125-26-330706 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-07-31 | 424B5 | 2026-08-03 | 0001193125-26-330792 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 4.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 8.54M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AccruedEmployeeBenefitsCurrent | Accrued Employee Benefits, Current | USD | 10.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 5.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 10.15M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -1.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 1.04B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 11.03M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 378,000 | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-23 | 0001564590-20-012202 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 30.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 13.56M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | Assets | Assets | USD | 406.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 354.42M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 2,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 1.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 252.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 251.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 211.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesNoncurrent | Debt Securities, Available-for-sale, Noncurrent | USD | 39.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 1.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 107.27M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 233.25M | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-12 | 0001564590-19-042891 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 110.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 26.05M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 300.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 64.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 64.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 6,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -186.86M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ConversionOfStockAmountIssued1 | Conversion of Stock, Amount Issued | USD | 3.00M | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-23 | 0001564590-20-012202 |
| us-gaap | DebtSecuritiesAvailableForSaleAllowanceForCreditLoss | Debt Securities, Available-for-sale, Allowance for Credit Loss | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | DeferredCostsCurrent | Deferred Costs, Current | USD | 402,000 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-06 | 0000950170-24-053535 | |
| us-gaap | DeferredFinanceCostsCurrentNet | Debt Issuance Costs, Current, Net | USD | 117,000 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-06 | 0001564590-23-003175 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 6.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | DeferredRevenueNoncurrent | Deferred Revenue, Noncurrent | USD | 4.45M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 161.14M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 28.92M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 66.00M | 2021-12-31 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001564590-22-037497 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 87.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 2.08M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 29.72M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 161.14M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | DefinedContributionPlanCostRecognized | Defined Contribution Plan, Cost | USD | 1.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | Depreciation | Depreciation | USD | 1.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -2.81 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.66 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-10 | 0001564590-22-019268 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -2.81 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | 0.485 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | -0.01 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.155 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.007 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.09 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | 0.888 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 83.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 29.91M | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-12 | 0000950170-25-107332 |
| us-gaap | ImpairmentOfLongLivedAssetsHeldForUse | Impairment of Long-Lived Assets Held-for-use | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -185.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 573,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 573,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxPaidStateAndLocalAfterRefundReceived | IncomeTaxPaidStateAndLocalAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | -3.34M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -1.45M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 7,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 1.07M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 53,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 6.11M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | -2.06M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-07 | 0000950170-23-060224 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 2.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | IncreaseDecreaseInDeferredLiabilities | Increase (Decrease) in Deferred Liabilities | USD | 28,000 | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | -8.05M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 11.65M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | InterestExpense | Interest Expense | USD | 61,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 10.56M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | InterestReceivableCurrent | Interest Receivable, Current | USD | 1.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 10.63M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | LeaseAndRentalExpense | Operating Leases, Rent Expense | USD | 1.10M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-23 | 0001564590-20-012202 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 2.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 699,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 473,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-04 | 0001193125-25-264720 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 533,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 532,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 815,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 124,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | Liabilities | Liabilities | USD | 54.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 406.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 48.98M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | LiabilitiesNoncurrent | Liabilities, Noncurrent | USD | 5.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 156.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 49.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -179.85M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -185.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 10.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 222.97M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -196.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 86.60M | 2026-01-21 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OperatingLeaseImpairmentLoss | Operating Lease, Impairment Loss | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 1.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 1.24M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 680,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 1.23M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 1.18M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 1.10M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 81,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-12 | 0001564590-19-042891 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 81,000 | 2019-12-31 | 2020 | Q3 | 10-Q | 2020-11-12 | 0001564590-20-053586 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 81,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 281,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-12 | 0001564590-19-042891 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.1 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 28,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-08 | 0001564590-21-055240 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 7.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -1.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -1.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | OtherLiabilitiesCurrent | Other Liabilities, Current | USD | 1.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 681,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | 333,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 179,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0001564590-22-009634 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 306,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0001564590-22-009634 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 103.97M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 5.18M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2019-06-21 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2019-06-21 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-23 | 0001564590-20-012202 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 12.55M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-14 | 0001564590-22-037497 | |
| us-gaap | PrepaidExpenseCurrent | Prepaid Expense, Current | USD | 17.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 105.40M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0001564590-22-009634 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 116.00M | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-23 | 0001564590-20-012202 |
| us-gaap | ProceedsFromPaymentsForOtherFinancingActivities | Proceeds from (Payments for) Other Financing Activities | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-25 | 0000950170-24-035912 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 158.65M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 1,000 | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 8.64M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 1.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -185.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ProFormaWeightedAverageSharesOutstandingDiluted | Pro Forma Weighted Average Shares Outstanding, Diluted | shares | 3.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 13.29M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 8.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 149.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 721,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 494,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 3.23M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -682.98M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | Revenues | Revenues | USD | 26.81M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 5.08M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0001564590-22-009634 |
| us-gaap | SegmentReportingOtherItemAmount | SegmentReportingOtherItemAmount | USD | -13.71M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | SellingGeneralAndAdministrativeExpense | Selling, General and Administrative Expense | USD | 73.97M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 30.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.79 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.81 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.8 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.027 | 2018-01-01 | 2018-06-30 | 2019 | Q2 | 10-Q | 2019-08-14 | 0001564590-19-032126 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.046 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 105.55M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 5.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 11.45 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 12.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 281,722 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 178,004 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 21.15 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 868,987 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 531,869 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 11.53 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 184.39M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 10.15M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 13.84 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 502,638 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-23 | 0001564590-20-012202 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 8.59 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | USD/shares | 15.09 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 10.99 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 15.94 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 352.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.101 | 2019-06-05 | 2019-06-06 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011760 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 1.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 941,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 149.45M | 2019-04-01 | 2019-06-30 | 2019 | Q3 | 10-Q | 2019-11-12 | 0001564590-19-042891 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 3.52M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | SubleaseIncome | Sublease Income | USD | 400,000 | 2025-09-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | -4.50M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-16 | 0001193125-26-108362 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 65.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 37.45M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-10 | 0001564590-22-019268 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 65.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001193125-26-445326 |